Lantern Pharma Inc
LTRN3.260USD
+0.020+0.62%
收盤 12/19, 16:00（美東）報價延遲15分鐘
35.99M總市值
虧損本益比TTM
關於 Lantern Pharma Inc 公司
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc簡介
公司代碼LTRN
公司名稱Lantern Pharma Inc
上市日期Jun 11, 2020
CEOSharma (Panna L)
員工數量24
證券類型Ordinary Share
年結日Jun 11
公司地址1920 Mckinney Avenue
城市DALLAS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編75201
電話19722771136
網址https://www.lanternpharma.com/
公司代碼LTRN
上市日期Jun 11, 2020
CEOSharma (Panna L)
Lantern Pharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
其他
72.28%
持股股東
持股股東
佔比
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
其他
72.28%
股東類型
持股股東
佔比
Corporation
13.19%
Venture Capital
9.08%
Investment Advisor
7.80%
Investment Advisor/Hedge Fund
2.08%
Hedge Fund
1.49%
Individual Investor
0.41%
Research Firm
0.09%
其他
65.86%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
75
2.28M
21.15%
-484.54K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bios Equity Partners, LP.
1.08M
9.96%
-157.85K
-12.79%
Jun 30, 2025
Biological Mimetics, Inc
844.13K
7.82%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.84%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Jun 30, 2025
CM Management, LLC
200.00K
1.85%
--
--
Jun 30, 2025
Renaissance Technologies LLC
90.60K
0.84%
+1.80K
+2.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
91.89K
0.85%
+1.39K
+1.53%
Jun 30, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Jun 30, 2025
GWM Advisors LLC
56.51K
0.52%
-3.42K
-5.70%
Jun 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
--
--
Jul 23, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Lantern Pharma Inc的前五大股東是誰？
Lantern Pharma Inc的前五大股東如下：
Bios Equity Partners, LP.持有股份：1.08M佔總股份比例：9.96%。
Biological Mimetics, Inc持有股份：844.13K佔總股份比例：7.82%。
Prophase Labs Inc持有股份：631.20K佔總股份比例：5.84%。
The Vanguard Group, Inc.持有股份：363.72K佔總股份比例：3.37%。
CM Management, LLC持有股份：200.00K佔總股份比例：1.85%。
Bios Equity Partners, LP.持有股份：1.08M佔總股份比例：9.96%。
Biological Mimetics, Inc持有股份：844.13K佔總股份比例：7.82%。
Prophase Labs Inc持有股份：631.20K佔總股份比例：5.84%。
The Vanguard Group, Inc.持有股份：363.72K佔總股份比例：3.37%。
CM Management, LLC持有股份：200.00K佔總股份比例：1.85%。
Lantern Pharma Inc的前三大股東類型是什麼？
Lantern Pharma Inc 的前三大股東類型分別是：
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
有多少機構持有Lantern Pharma Inc(LTRN)的股份？
截至2025Q3，共有75家機構持有Lantern Pharma Inc的股份，合計持有的股份價值約為2.28M，占公司總股份的21.15% 。與2025Q2相比，機構持股有所增加，增幅為-13.91%。
哪個業務部門對Lantern Pharma Inc的收入貢獻最大？
在--，--業務部門對Lantern Pharma Inc的收入貢獻最大，創收--，占總收入的--% 。
